LinkedIn Profile

Access Immune Pharmaceuticals historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
nasdaq:imnp 940900 Mar 24th, 2024 12:00AM Immune Pharmaceuticals Inc. 1.6K 6.00 Open Mar 24th, 2024 01:34AM Mar 24th, 2024 01:34AM Immune Pharmaceuticals Inc. (OTCQB: IMNP) is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Immune’s lead program, bertilimumab, is a first-in-class, fully human monoclonal antibody that targets and lowers levels of eotaxin-1, a chemokine that plays a role in immune responses and attracts eosinophils to the site of inflammation. By neutralizing eotaxin-1, bertilimumab may prevent the migration of eosinophils and other cells, thus helping to relieve associated inflammatory conditions. Currently, Immune is conducting two phase 2 clinical trials to test bertilimumab in patients suffering from bullous pemphigoid and ulcerative colitis, respectively. Bertilimumab may have application in other indications, including atopic dermatitis, asthma, and other diseases. Immune is also developing NanoCyclo, a topical formulation of cyclosporine, for atopic dermatitis and psoriasis, which is currently in late-stage preclinical testing. Open Pharmaceuticals, Nanomabs, Monoclonal Antibodies, biotechnology, bullous pemphigoid , and biopharmaceuticals Open 1 Bridge Plaza N Fort Lee New Jersey US 07024 Immune Pharmaceuticals Pharmaceuticals & Biotechnology
nasdaq:imnp 940900 Mar 23rd, 2024 12:00AM Immune Pharmaceuticals Inc. 1.6K 6.00 Open Mar 22nd, 2024 11:46PM Mar 23rd, 2024 06:55PM Immune Pharmaceuticals Inc. (OTCQB: IMNP) is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Immune’s lead program, bertilimumab, is a first-in-class, fully human monoclonal antibody that targets and lowers levels of eotaxin-1, a chemokine that plays a role in immune responses and attracts eosinophils to the site of inflammation. By neutralizing eotaxin-1, bertilimumab may prevent the migration of eosinophils and other cells, thus helping to relieve associated inflammatory conditions. Currently, Immune is conducting two phase 2 clinical trials to test bertilimumab in patients suffering from bullous pemphigoid and ulcerative colitis, respectively. Bertilimumab may have application in other indications, including atopic dermatitis, asthma, and other diseases. Immune is also developing NanoCyclo, a topical formulation of cyclosporine, for atopic dermatitis and psoriasis, which is currently in late-stage preclinical testing. Open Pharmaceuticals, Nanomabs, Monoclonal Antibodies, biotechnology, bullous pemphigoid , and biopharmaceuticals Open 1 Bridge Plaza N Fort Lee New Jersey US 07024 Immune Pharmaceuticals Pharmaceuticals & Biotechnology
nasdaq:imnp 940900 Mar 22nd, 2024 12:00AM Immune Pharmaceuticals Inc. 1.6K 6.00 Open Mar 21st, 2024 11:36PM Mar 22nd, 2024 06:44PM Immune Pharmaceuticals Inc. (OTCQB: IMNP) is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Immune’s lead program, bertilimumab, is a first-in-class, fully human monoclonal antibody that targets and lowers levels of eotaxin-1, a chemokine that plays a role in immune responses and attracts eosinophils to the site of inflammation. By neutralizing eotaxin-1, bertilimumab may prevent the migration of eosinophils and other cells, thus helping to relieve associated inflammatory conditions. Currently, Immune is conducting two phase 2 clinical trials to test bertilimumab in patients suffering from bullous pemphigoid and ulcerative colitis, respectively. Bertilimumab may have application in other indications, including atopic dermatitis, asthma, and other diseases. Immune is also developing NanoCyclo, a topical formulation of cyclosporine, for atopic dermatitis and psoriasis, which is currently in late-stage preclinical testing. Open Pharmaceuticals, Nanomabs, Monoclonal Antibodies, biotechnology, bullous pemphigoid , and biopharmaceuticals Open 1 Bridge Plaza N Fort Lee New Jersey US 07024 Immune Pharmaceuticals Pharmaceuticals & Biotechnology
nasdaq:imnp 940900 Mar 21st, 2024 12:00AM Immune Pharmaceuticals Inc. 1.6K 6.00 Open Mar 20th, 2024 11:49PM Mar 21st, 2024 05:27PM Immune Pharmaceuticals Inc. (OTCQB: IMNP) is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Immune’s lead program, bertilimumab, is a first-in-class, fully human monoclonal antibody that targets and lowers levels of eotaxin-1, a chemokine that plays a role in immune responses and attracts eosinophils to the site of inflammation. By neutralizing eotaxin-1, bertilimumab may prevent the migration of eosinophils and other cells, thus helping to relieve associated inflammatory conditions. Currently, Immune is conducting two phase 2 clinical trials to test bertilimumab in patients suffering from bullous pemphigoid and ulcerative colitis, respectively. Bertilimumab may have application in other indications, including atopic dermatitis, asthma, and other diseases. Immune is also developing NanoCyclo, a topical formulation of cyclosporine, for atopic dermatitis and psoriasis, which is currently in late-stage preclinical testing. Open Pharmaceuticals, Nanomabs, Monoclonal Antibodies, biotechnology, bullous pemphigoid , and biopharmaceuticals Open 1 Bridge Plaza N Fort Lee New Jersey US 07024 Immune Pharmaceuticals Pharmaceuticals & Biotechnology
nasdaq:imnp 940900 Mar 20th, 2024 12:00AM Immune Pharmaceuticals Inc. 1.6K 6.00 Open Mar 20th, 2024 12:20AM Mar 20th, 2024 07:28PM Immune Pharmaceuticals Inc. (OTCQB: IMNP) is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Immune’s lead program, bertilimumab, is a first-in-class, fully human monoclonal antibody that targets and lowers levels of eotaxin-1, a chemokine that plays a role in immune responses and attracts eosinophils to the site of inflammation. By neutralizing eotaxin-1, bertilimumab may prevent the migration of eosinophils and other cells, thus helping to relieve associated inflammatory conditions. Currently, Immune is conducting two phase 2 clinical trials to test bertilimumab in patients suffering from bullous pemphigoid and ulcerative colitis, respectively. Bertilimumab may have application in other indications, including atopic dermatitis, asthma, and other diseases. Immune is also developing NanoCyclo, a topical formulation of cyclosporine, for atopic dermatitis and psoriasis, which is currently in late-stage preclinical testing. Open Pharmaceuticals, Nanomabs, Monoclonal Antibodies, biotechnology, bullous pemphigoid , and biopharmaceuticals Open 1 Bridge Plaza N Fort Lee New Jersey US 07024 Immune Pharmaceuticals Pharmaceuticals & Biotechnology
nasdaq:imnp 940900 Mar 19th, 2024 12:00AM Immune Pharmaceuticals Inc. 1.6K 6.00 Open Mar 18th, 2024 11:24PM Mar 19th, 2024 06:00PM Immune Pharmaceuticals Inc. (OTCQB: IMNP) is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Immune’s lead program, bertilimumab, is a first-in-class, fully human monoclonal antibody that targets and lowers levels of eotaxin-1, a chemokine that plays a role in immune responses and attracts eosinophils to the site of inflammation. By neutralizing eotaxin-1, bertilimumab may prevent the migration of eosinophils and other cells, thus helping to relieve associated inflammatory conditions. Currently, Immune is conducting two phase 2 clinical trials to test bertilimumab in patients suffering from bullous pemphigoid and ulcerative colitis, respectively. Bertilimumab may have application in other indications, including atopic dermatitis, asthma, and other diseases. Immune is also developing NanoCyclo, a topical formulation of cyclosporine, for atopic dermatitis and psoriasis, which is currently in late-stage preclinical testing. Open Pharmaceuticals, Nanomabs, Monoclonal Antibodies, biotechnology, bullous pemphigoid , and biopharmaceuticals Open 1 Bridge Plaza N Fort Lee New Jersey US 07024 Immune Pharmaceuticals Pharmaceuticals & Biotechnology
nasdaq:imnp 940900 Mar 18th, 2024 12:00AM Immune Pharmaceuticals Inc. 1.6K 6.00 Open Mar 17th, 2024 11:46PM Mar 18th, 2024 07:12PM Immune Pharmaceuticals Inc. (OTCQB: IMNP) is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Immune’s lead program, bertilimumab, is a first-in-class, fully human monoclonal antibody that targets and lowers levels of eotaxin-1, a chemokine that plays a role in immune responses and attracts eosinophils to the site of inflammation. By neutralizing eotaxin-1, bertilimumab may prevent the migration of eosinophils and other cells, thus helping to relieve associated inflammatory conditions. Currently, Immune is conducting two phase 2 clinical trials to test bertilimumab in patients suffering from bullous pemphigoid and ulcerative colitis, respectively. Bertilimumab may have application in other indications, including atopic dermatitis, asthma, and other diseases. Immune is also developing NanoCyclo, a topical formulation of cyclosporine, for atopic dermatitis and psoriasis, which is currently in late-stage preclinical testing. Open Pharmaceuticals, Nanomabs, Monoclonal Antibodies, biotechnology, bullous pemphigoid , and biopharmaceuticals Open 1 Bridge Plaza N Fort Lee New Jersey US 07024 Immune Pharmaceuticals Pharmaceuticals & Biotechnology
nasdaq:imnp 940900 Mar 17th, 2024 12:00AM Immune Pharmaceuticals Inc. 1.6K 6.00 Open Mar 17th, 2024 01:14AM Mar 17th, 2024 01:14AM Immune Pharmaceuticals Inc. (OTCQB: IMNP) is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Immune’s lead program, bertilimumab, is a first-in-class, fully human monoclonal antibody that targets and lowers levels of eotaxin-1, a chemokine that plays a role in immune responses and attracts eosinophils to the site of inflammation. By neutralizing eotaxin-1, bertilimumab may prevent the migration of eosinophils and other cells, thus helping to relieve associated inflammatory conditions. Currently, Immune is conducting two phase 2 clinical trials to test bertilimumab in patients suffering from bullous pemphigoid and ulcerative colitis, respectively. Bertilimumab may have application in other indications, including atopic dermatitis, asthma, and other diseases. Immune is also developing NanoCyclo, a topical formulation of cyclosporine, for atopic dermatitis and psoriasis, which is currently in late-stage preclinical testing. Open Pharmaceuticals, Nanomabs, Monoclonal Antibodies, biotechnology, bullous pemphigoid , and biopharmaceuticals Open 1 Bridge Plaza N Fort Lee New Jersey US 07024 Immune Pharmaceuticals Pharmaceuticals & Biotechnology
nasdaq:imnp 940900 Mar 16th, 2024 12:00AM Immune Pharmaceuticals Inc. 1.6K 6.00 Open Mar 15th, 2024 11:16PM Mar 16th, 2024 07:00PM Immune Pharmaceuticals Inc. (OTCQB: IMNP) is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Immune’s lead program, bertilimumab, is a first-in-class, fully human monoclonal antibody that targets and lowers levels of eotaxin-1, a chemokine that plays a role in immune responses and attracts eosinophils to the site of inflammation. By neutralizing eotaxin-1, bertilimumab may prevent the migration of eosinophils and other cells, thus helping to relieve associated inflammatory conditions. Currently, Immune is conducting two phase 2 clinical trials to test bertilimumab in patients suffering from bullous pemphigoid and ulcerative colitis, respectively. Bertilimumab may have application in other indications, including atopic dermatitis, asthma, and other diseases. Immune is also developing NanoCyclo, a topical formulation of cyclosporine, for atopic dermatitis and psoriasis, which is currently in late-stage preclinical testing. Open Pharmaceuticals, Nanomabs, Monoclonal Antibodies, biotechnology, bullous pemphigoid , and biopharmaceuticals Open 1 Bridge Plaza N Fort Lee New Jersey US 07024 Immune Pharmaceuticals Pharmaceuticals & Biotechnology
nasdaq:imnp 940900 Mar 15th, 2024 12:00AM Immune Pharmaceuticals Inc. 1.6K 6.00 Open Mar 15th, 2024 12:37AM Mar 15th, 2024 08:49AM Immune Pharmaceuticals Inc. (OTCQB: IMNP) is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Immune’s lead program, bertilimumab, is a first-in-class, fully human monoclonal antibody that targets and lowers levels of eotaxin-1, a chemokine that plays a role in immune responses and attracts eosinophils to the site of inflammation. By neutralizing eotaxin-1, bertilimumab may prevent the migration of eosinophils and other cells, thus helping to relieve associated inflammatory conditions. Currently, Immune is conducting two phase 2 clinical trials to test bertilimumab in patients suffering from bullous pemphigoid and ulcerative colitis, respectively. Bertilimumab may have application in other indications, including atopic dermatitis, asthma, and other diseases. Immune is also developing NanoCyclo, a topical formulation of cyclosporine, for atopic dermatitis and psoriasis, which is currently in late-stage preclinical testing. Open Pharmaceuticals, Nanomabs, Monoclonal Antibodies, biotechnology, bullous pemphigoid , and biopharmaceuticals Open 1 Bridge Plaza N Fort Lee New Jersey US 07024 Immune Pharmaceuticals Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.